A collaboration between Babraham Institute scientists and AstraZeneca provides new insights into the role of PTEN, a major cancer gene, in controlling cell growth and behaviour. PTEN is the second most commonly altered gene in human cancers, particularly prostate cancers, and this work could help to develop and target new treatments.
In a study in today's issue of Science, researchers at Albert Einstein College of Medicine, part of Montefiore Medicine, report that certain nerves sustain prostate cancer growth by triggering a switch that causes tumor vessels to proliferate. Their earlier research -- which first implicated nerves in fueling prostate cancer -- has prompted Montefiore-Einstein to conduct a pilot study testing whether beta blockers (commonly used for treating hypertension) can kill cancer cells in tumors of men diagnosed with prostate cancer.
Back-to-back discoveries from Cleveland Clinic demonstrate for the first time how a testosterone-related genetic abnormality can help predict individual patient responses to specific prostate cancer therapies. The studies, published in the Oct. 12 issue of JAMA Oncology, suggest that men who inherit this variant would benefit from a personalized treatment plan that targets specific hormonal pathways.
The world's 'better' countries, with greater access to healthcare, experience much higher rates of cancer incidence than the world's 'worse off' countries, according to new research from the University of Adelaide.
Future direction in prostate cancer imaging involves the development of androgen receptor based imaging using nonsteroidal antiandrogen agent for early diagnosis of prostate cancer.
Stromal tissue may provide novel targets to disrupt tumor supply lines.
UAlberta researchers have created two new imaging agents that could help physicians visualize the formation of tumor-associated blood vessels, keep track of tumor growth and possibly generate new therapies.
Therapy options are limited for men with advanced-stage, metastatic castration-resistant prostate cancer, but a new treatment protocol offers hope. In the featured article of The Journal of Nuclear Medicine's October issue, German researchers report on their novel dosing regimen for actinium-225-labeled targeted alpha therapy of patients with prostate specific membrane antigen (PSMA)-positive tumors. The protocol balances treatment response with toxicity concerns to provide the most effective therapy with the least side effects.
A new study carried out by the University of Oxford has used flat worms to look at the role of migrating stem cells in cancer. Researchers from the Aboobaker lab in the Department of Zoology used the worms (planarians) which are known for their ability to regenerate their tissues and organs repeatedly. By understanding how stem cells are programmed to move, what activates them and how they follow a correct path, researchers may be able to design new treatments for cancer.
Family Medicine and Community Health Journal Volume 5, Issue Number 2 publishes as a special issue entitled 'Primary care and cancer', guest editor: Professor Li Li, UH Cleveland Medical Center, Cleveland, Ohio, USA.